natgillin/translations-raw huggingface dataset:
Change in clinical status of patients with previously controlled type 2 diabetes A patient with type 2 diabetes previously well controlled on Ristfor who develops laboratory abnormalities or clinical illness (especially vague and poorly defined illness) should be evaluated promptly for evidence of ketoacidosis or lactic acidosis. 
Spremembe kliničnega statusa pri bolnikih s predhodno nadzorovano sladkorno boleznijo tipa 2 Pri bolnikih s sladkorno boleznijo tipa 2, predhodno dobro nadzorovano z jemanjem zdravila Ristfor, pri katerih se pojavijo nenormalni izvidi laboratorijskih preiskav ali klinične bolezni (zlasti nejasne ali slabo opredeljene bolezni), je treba čim prej ugotoviti, če imajo ketoacidozo ali laktacidozo.
Table 2: HbA1c results in placebo-controlled combination therapy studies of sitagliptin and metformin* 
Preglednica 2: Vrednosti HbA1c v s placebom nadzorovanih študijah kombiniranega zdravljenja s sitagliptinom in metforminom*
If you need to have an injection of a contrast medium that contains iodine into your bloodstream, for example, in the context of an X-ray or scan, you must stop taking Ristfor before or at the time of the injection. 
Če vam bodo v krvni obtok injicirali kontrastno sredstvo, ki vsebuje jod, na primer zaradi rentgenskega ali drugega slikanja, morate pred časom injiciranja ali v tem času prenehati z jemanjem zdravila Ristfor.
Sitagliptin was modestly removed by haemodialysis (13.5 % over a 3- to 4-hour haemodialysis session starting 4 hours post-dose). 
Sitagliptin se je zmerno odstranil s hemodializo (13,5 % pri 3- do 4-urni hemodializi, ki se začne 4 ure po odmerku).
Placebo-corrected mean change in HbA1c (%) (95 % CI) 
S placebom korigirana povprečna sprememba vrednosti HbA1c (%) (95-odstotni IZ)
Since co-administration of a high-fat meal with sitagliptin had no effect on the pharmacokinetics, sitagliptin may be administered with or without food. 
Sočasno zaužitje obroka z veliko maščobami ni vplivalo na farmakokinetiko, zato se sitagliptin lahko jemlje s hrano ali brez nje.
Your doctor will decide when you must stop and when to restart your treatment with Ristfor. 
Zdravnik se bo odločil, kdaj morate z jemanjem zdravila Ristfor prenehati in kdaj lahko nadaljujete.
Stop taking Ristfor for a short time if you have a condition that may be associated with dehydration (significant loss of body fluids) such as severe vomiting, diarrhoea, fever, exposure to heat or if you drink less fluid than normal. 
Za kratek čas prenehajte jemati zdravilo Ristfor, če imate stanje, ki je lahko povezano z dehidracijo (znatna izguba telesnih tekočin), kot je hudo bruhanje, driska, zvišana telesna temperatura, izpostavljenost vročini ali če pijete manj tekočine, kot običajno.
The following data are findings in studies performed with sitagliptin or metformin individually. 
Naslednji podatki so ugotovitve študij, opravljenih s sitagliptinom in metforminom samim.
You should continue the diet recommended by your doctor during treatment with this medicine and take care that your carbohydrate intake is equally distributed over the day. 
Med zdravljenjem s tem zdravilom nadaljujte z dieto, ki vam jo je priporočil zdravnik, in pazite, da ogljikove hidrate uživate enakomerno čez ves dan.
Table 1: The frequency of adverse reactions identified from placebo-controlled clinical studies of sitagliptin and metformin alone, and post-marketing experience 
Preglednica 1: Pogostnost neželenih učinkov iz s placebom nadzorovanih kliničnih študij sitagliptina in metformina samega in iz obdobja trženja zdravila
Reduction in fasting plasma glucose (FPG) was observed at 3 weeks, the first time point at which FPG was measured. 
Znižanje glukoze v plazmi na tešče so opazili po 3 tednih, ko so jo prvič merili.
Lactic acidosis, a rare but serious metabolic complication, most often occurs at acute worsening of renal function or cardiorespiratory illness or sepsis. 
Laktacidoza, redek a resen presnovni zaplet, se najpogosteje pojavi ob akutnem poslabšanju delovanja ledvic, ob kardiorespiratorni bolezni ali sepsi.
Following administration of a dose of 850 mg, a 40 % lower plasma peak concentration, a 25 % decrease in AUC and a 35 min prolongation of time to peak plasma concentration was observed. 
Po dajanju 850-miligramskega odmerka so opazili za 40 % manjšo največjo koncentracijo v plazmi, za 25 % zmanjšano vrednost AUC in 35-minutno podaljšanje časa za doseg največje koncentracije v plazmi.
Ristfor is contraindicated in patients with GFR < 30 mL/min and should be temporarily discontinued during conditions with the potential to alter renal function (see section 4.3). 
Zdravilo Ristfor je kontraindicirano pri bolnikih z GFR < 30 ml/min in ga je treba začasno ukiniti, če se pojavijo stanja, ki spremenijo delovanje ledvic (glejte poglavje 4.3).
In addition, osteoarthritis and pain in extremity were reported with frequency uncommon (> 0.5 % higher among sitagliptin users than that in the control group). 
Poleg tega so občasno poročali o osteoartritisu in bolečinah v okončinah (> 0,5 % pogosteje pri bolnikih, ki so prejemali sitagliptin, kot pri kontrolni skupini).
The incidence of hypoglycaemia in the sitagliptin group (4.9 %) was significantly lower than that in the glipizide group (32.0 %). 
Pojavnost hipoglikemije je bila v skupini, ki je prejemala sitagliptin (4,9 %), pomembno manjša kot v skupini, ki je prejemala glipizid
If this happens, you must stop taking Ristfor and contact a doctor or the nearest hospital immediately, as lactic acidosis may lead to coma. 
V tem primeru morate prenehati jemati zdravilo Ristfor in se takoj obrniti na zdravnika ali najbližjo bolnišnico, saj lahko laktacidoza vodi v komo.
Stop taking Ristfor and contact a doctor or the nearest hospital immediately if you experience some of the symptoms of lactic acidosis, as this condition may lead to coma. 
Takoj prenehajte jemati zdravilo Ristfor in se obrnite na zdravnika ali najbližjo bolnišnico, če se pojavijo nekateri od simptomov laktacidoze, saj lahko to stanje vodi v komo.
Overall, sitagliptin improved glycaemic control when used as monotherapy or in combination treatment. 
Na splošno je sitagliptin izboljšal urejenost glikemije, če se je uporabljal sam ali v kombinaciji z drugimi zdravili.
Six metabolites were detected at trace levels and are not expected to contribute to the plasma DPP-4 inhibitory activity of sitagliptin. 
Šest presnovkov je bilo odkritih v sledeh, zanje pa se ne pričakuje, da sodelujejo pri zaviralnem delovanju sitagliptina na DPP-4 v plazmi.
GFR mL/min Metformin 
GFR ml/min metformin sitagliptin
Go to the hospital if you have symptoms of lactic acidosis such as feeling cold or uncomfortable, severe nausea or vomiting, stomach ache, unexplained weight loss, muscular cramps, or rapid breathing (see section “Warnings and precautions”). 
Pojdite v bolnišnico, če imate simptome laktacidoze, kot so mrazenje ali neprijeten občutek, močno siljenje na bruhanje ali bruhanje, bolečine v trebuhu, nepojasnjeno hujšanje, mišični krči ali hitro dihanje (glejte poglavje "Opozorila in previdnostni ukrepi").
Following administration of 0.25 mg digoxin concomitantly with 100 mg of sitagliptin daily for 10 days, the plasma AUC of digoxin was increased on average by 11 %, and the plasma Cmax on average by 18 %. 
Po 10-dnevnem odmerjanju 0,25 mg digoksina v kombinaciji s 100 mg sitagliptina dnevno se je vrednost AUC digoksina v plazmi povečala povprečno za 11 %, vrednost Cmax v plazmi pa povprečno za 18 %.
Symptoms of lactic acidosis include: - vomiting - stomach ache (abdominal pain) - muscle cramps - a general feeling of not being well with severe tiredness - difficulty in breathing - reduced body temperature and heartbeat 
Simptomi laktacidoze vključujejo: - bruhanje - bolečino v trebuhu (abdominalna bolečina) - mišične krče - splošno slabo počutje s hudo utrujenostjo - težave z dihanjem - znižano telesno temperaturo in počasen srčni utrip
In a clinical study sitagliptin had a small effect on plasma digoxin concentrations indicating that sitagliptin may be a mild inhibitor of p-glycoprotein. 
V klinični študiji je sitagliptin imel majhen učinek na koncentracijo digoksina v plazmi, kar kaže, da je sitagliptin lahko blagi zaviralec p-glikoproteina.
Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis. 
Sočasna uporaba zdravil, ki vplivajo na običajne ledvične tubularne transportne sisteme, ki so udeleženi pri izločanju metformina skozi ledvice (npr. prenašalci organskih kationov [OCT]2/ zaviralci beljakovine, ki je odgovorna za ekstruzijo več zdravil in toksinov [MATE - multidrug and toxin extrusion], kot so ranolazin, vandetanib, dolutegravir in cimetidin), bi lahko zvečala sistemsko izpostavljenost metforminu in tveganje za laktacidozo.
However, dizziness and drowsiness have been reported with sitagliptin, which may affect your ability to drive or use machines. 
Vendar pa so pri sitagliptinu poročali o pojavu omotice in zaspanosti, ki lahko vplivata na vašo sposobnost vožnje ali upravljanja strojev.
Additional adverse reactions associated with metformin include metallic taste (common); lactic acidosis, liver function disorders, hepatitis, urticaria, erythema, and pruritus (very rare). 
Dodatni neželeni učinki, povezani z metforminom, vključujejo kovinski okus (pogost), laktacidozo, okvaro delovanja jeter, hepatitis, urtikarijo, eritem in pruritus (zelo redki).
Therefore, a reduction in the dose of the sulphonylurea or insulin may be necessary. 
Zato je morda treba zmanjšati odmerek sulfonilsečnine ali insulina.
ACE-inhibitors may decrease the blood glucose levels. 
Zaviralci ACE lahko zmanjšajo koncentracijo glukoze v krvi.
Some medicinal products can adversely affect renal function, which may increase the risk of lactic acidosis, e.g. NSAIDs, including selective cyclo-oxygenase (COX) II inhibitors, ACE inhibitors, angiotensin II receptor antagonists and diuretics, especially loop diuretics. 
Nekatera zdravila lahko škodljivo vplivajo na delovanje ledvic, kar lahko zveča tveganje za laktacidozo, npr. nesteroidna protivnetna zdravila, vključno s selektivnimi zaviralci ciklooksigenaze (COX) II, zaviralci ACE, antagonisti receptorjev angiotenzina II in diuretiki, zlasti diuretiki Henlejeve zanke.
If you stop taking Ristfor 
Če ste prenehali jemati zdravilo Ristfor
What Ristfor is and what it is used for What you need to know before you take Ristfor How to take Ristfor 
Kaj je zdravilo Ristfor in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Ristfor Kako jemati zdravilo Ristfor Možni neželeni učinki
A bioequivalence study in healthy subjects demonstrated that the Ristfor (sitagliptin/metformin hydrochloride) combination tablets are bioequivalent to co-administration of sitagliptin phosphate and metformin hydrochloride as individual tablets. 
V bioekvivalenčni študiji pri zdravih osebah so pokazali, da so kombinirane tablete Ristfor (sitagliptin/metforminijev klorid) bioekvivalentne sočasni uporabi sitagliptinijevega fosfata in metforminijevega klorida v obliki posameznih tablet.
Pack of 50 x 1 film-coated tablets in perforated unit dose blisters. 
Pakiranje po 50 x 1 filmsko obložena tableta v perforiranih pretisnih omotih za enkratni odmerek.
You should not take this medicine during pregnancy or if you are breast-feeding. 
Med nosečnostjo ali dojenjem tega zdravila ne smete jemati.
The incidence of hypoglycaemia was 24.9 % for patients treated with sitagliptin, metformin, and insulin and 37.8 % for patients treated with placebo, metformin, and insulin. 
Pojavnost hipoglikemije je bila pri bolnikih, ki so prejemali sitagliptin, metformin in insulin, 24,9 %, pri bolnikih, ki so prejemali placebo, metformin in insulin, pa 37,8 %.
They work together to control blood sugar levels in adult patients with a form of diabetes called ‘type 2 diabetes mellitus'. 
Skupaj delujeta pri uravnavanju ravni sladkorja v krvi pri odraslih bolnikih s sladkorno boleznijo tipa 2.
- hypersensitivity to the active substances or to any of the excipients listed in section 6.1 (see sections 4.4 and 4.8); - any type of acute metabolic acidosis (such as lactic acidosis, diabetic ketoacidosis); - diabetic pre-coma; - severe renal failure (GFR< 30 mL/min) (see section 4.4); - acute conditions with the potential to alter renal function such as: dehydration, severe infection, shock, intravascular administration of iodinated contrast agents (see section 4.4); - acute or chronic disease which may cause tissue hypoxia such as: cardiac or respiratory failure, recent myocardial infarction, shock; - hepatic impairment; - acute alcohol intoxication, alcoholism; - breast-feeding. 
- preobčutljivosti na učinkovini ali katero koli pomožno snov, navedeno v poglavju 6.1 (glejte poglavji 4.4 in 4.8); - vseh vrstah akutne metabolične acidoze (kot sta laktacidoza, diabetična ketoacidoza); - stanju pred diabetično komo; - hudi ledvični odpovedi (GFR < 30 ml/min) (glejte poglavje 4.4); - akutnih stanjih, pri katerih obstaja možnost poslabšanja delovanja ledvic, kot so: dehidracija, huda okužba, šok, intravaskularna uporaba jodiranih kontrastnih sredstev (glejte poglavje 4.4); - akutnih ali kroničnih boleznih, ki lahko povzročijo hipoksijo tkiv, kot so: srčna ali respiratorna odpoved, nedavni miokardni infarkt, šok; - okvari jeter; - akutni zastrupitvi z alkoholom, alkoholizmu; - dojenju.
Ristfor must therefore not be used in women who are breast-feeding (see section 4.3). 
Zato ženske, ki dojijo, zdravila Ristfor ne smejo jemati (glejte poglavje 4.3).
In clinical trials, sitagliptin as monotherapy improved glycaemic control with significant reductions in haemoglobin A1c (HbA1c) and fasting and postprandial glucose. 
V kliničnih preskušanjih je samostojno zdravljenje s sitagliptinom izboljšalo urejenost glikemije s pomembnim zmanjšanjem ravni hemoglobina A1c (HbA1c) in glukoze na tešče ter po obroku.
GLP-1 also lowers glucagon secretion from pancreatic alpha cells, leading to reduced hepatic glucose production. 
GLP-1 tudi zmanjša izločanje glukagona iz celic alfa trebušne slinavke, kar povzroči zmanjšano nastajanje glukoze v jetrih.
Among patients taking metformin, baseline HbA1c was 8.70 % and baseline insulin dose was 37 IU/day. 
Med bolniki, ki so prejemali metformin, je bila začetna vrednost HbA1c 8,70 %, začetni odmerek insulina pa je bil 37 i.e./dan.
These included hypoglycaemia (frequency very common with sulphonylurea or insulin), constipation (common with sulphonylurea), peripheral oedema (common with pioglitazone), and headache and dry mouth (uncommon with insulin). 
Ti so vključevali hipoglikemijo (pogostnost - zelo pogosta s sulfonilsečnino ali insulinom), zaprtje (pogostnost - pogosta s sulfonilsečnino), periferni edem (pogostnost - pogosta s pioglitazonom) ter glavobol in suha usta (pogostnost - občasna z insulinom).
Multi-pack containing 196 (2 packs of 98) film-coated tablets Multi-pack containing 168 (2 packs of 84) film-coated tablets 
Multi pakiranje po 196 (2 pakiranji po 98) filmsko obloženih tablet Multi pakiranje po 168 (2 pakiranji po 84) filmsko obloženih tablet
Sitagliptin phosphate is an orally-active, potent, and highly selective inhibitor of the dipeptidyl peptidase 4 (DPP-4) enzyme for the treatment of type 2 diabetes. 
Sitagliptinijev fosfat je peroralno aktiven, močan in zelo selektiven zaviralec encima dipeptidil-peptidaze 4 (DPP-4) in se uporablja za zdravljenje sladkorne bolezni tipa 2.
If you take more than the prescribed dosage of this medicine, contact your doctor immediately. 
Če ste vzeli večji odmerek zdravila Ristfor, kot bi smeli Če ste vzeli večji odmerek tega zdravila od predpisanega, se takoj posvetujte z zdravnikom.
For patients switching from co-administration of sitagliptin and metformin For patients switching from co-administration of sitagliptin and metformin, Ristfor should be initiated at the dose of sitagliptin and metformin already being taken. 
Pri bolnikih, ki prehajajo s sočasnega jemanja sitagliptina in metformina Pri bolnikih, ki prehajajo s sočasnega jemanja sitagliptina in metformina, je treba zdravljenje z zdravilom Ristfor začeti z odmerkom sitagliptina in metformina, ki ga že jemljejo.
Hepatic impairment Ristfor must not be used in patients with hepatic impairment (see section 5.2). 
Jetrna okvara Zdravila Ristfor se pri bolnikih z okvaro jeter ne sme uporabljati (glejte poglavje 5.2).
If you need to have major surgery you must stop taking Ristfor during and for some time after the procedure. 
Če morate na večji kirurški poseg, morate v času posega in še nekaj časa po tem prenehati z jemanjem zdravila Ristfor.
• sitagliptin belongs to a class of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors) 
• Sitagliptin spada v skupino zdravil, ki se imenujejo zaviralci DPP-4 (zaviralci dipeptidil peptidaze 4).
If necessary, the dose of the anti-hyperglycaemic medicinal product should be adjusted during therapy with the other medicinal product and on its discontinuation. 
Po potrebi odmerek antidiabetikov prilagodite med zdravljenjem z drugim zdravilom in ob ukinitvi drugih zdravil.
Your doctor may reduce the dose of your sulphonylurea or insulin 
Zdravnik vam lahko zmanjša odmerek sulfonilsečnine ali insulina.
The mean volume of distribution at steady state following a single 100-mg intravenous dose of sitagliptin to healthy subjects is approximately 198 litres. 
Pri zdravih osebah je povprečni volumen porazdelitve v stanju dinamičnega ravnovesja po enkratnem 100 mg intravenskem odmerku približno 198 litrov.
The dose should provide sitagliptin dosed as 50 mg twice daily (100 mg total daily dose) and a dose of metformin similar to the dose already being taken. 
Odmerek mora zagotoviti 50 mg sitagliptina dvakrat na dan (skupni dnevni odmerek 100 mg) in podoben odmerek metformina, kot ga že jemljejo.
• certain medicines for the treatment of high blood pressure (ACE inhibitors and angiotensin II 
• nekatera zdravila za zdravljenje visokega krvnega tlaka (zaviralci ACE in antagonisti receptorjev angiotenzina II)
The DPP-4 inhibitors are a class of agents that act as incretin enhancers. 
Zaviralci DPP-4 so učinkovine, ki delujejo kot spodbujevalci inkretina.
50 x 1 film-coated tablets 
50 x 1 filmsko obložena tableta
The reduction in HbA1c for patients treated with sitagliptin, metformin, and insulin was -1.35 % compared to -0.90 % for patients treated with placebo, metformin, and insulin, a difference of -0.45 % [95 % CI: -0.62, -0.29]. 
Zmanjšanje vrednosti HbA1c je pri bolnikih, zdravljenih s sitagliptinom, metforminom in insulinom, znašalo -1,35 %, pri bolnikih, ki so prejemali placebo, metformin in insulin, pa -0,90 %; razlika je znašala -0,45 % [95 % IZ: -0,62, -0,29].
Metformin may act via three mechanisms: - by reduction of hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis - in muscle, by modestly increasing insulin sensitivity, improving peripheral glucose uptake and utilisation - by delaying intestinal glucose absorption. 
Metformin lahko deluje na tri načine: - z zaviranjem glukoneogeneze in glikogenolize zmanjšuje nastajanje glukoze v jetrih; - v mišicah zmerno poveča občutljivost za insulin, izboljša periferni vnos in izkoriščanje glukoze; - upočasni absorpcijo glukoze v črevesju.
Very rare: decreased vitamin B12 levels, hepatitis (a problem with your liver), hives, redness of the skin (rash) or itching 
Zelo redki: znižane ravni vitamina B12, hepatitis (bolezen jeter), koprivnica, rdečica kože (izpuščaj) ali srbenje
Ristfor with alcohol 
Zdravilo Ristfor skupaj z alkoholom
Among patients taking metformin, at Week 24, the increase in daily insulin dose was 19 IU/day in patients treated with sitagliptin and 24 IU/day in patients treated with placebo. 
Med bolniki, ki so prejemali metformin, je pri bolnikih, zdravljenih s sitagliptinom, v 24. tednu povečanje dnevnega odmerka insulina znašalo 19 i.e./dan, pri bolnikih, ki so prejemali placebo, pa 24 i.e./dan.
The following statements reflect the pharmacokinetic properties of the individual active substances of Ristfor. 
V nadaljevanju so naštete farmakokinetične lastnosti posameznih učinkovin v zdravilu Ristfor.
Patients treated with sitagliptin had a modest increase in body weight (+1.1 kg) compared to those given placebo. 
Bolnikom, ki so prejemali sitagliptin, se je telesna masa v primerjavi z bolniki, ki so prejemali placebo, zmerno povečala (+1,1 kg).
Sitagliptin differs in chemical structure and pharmacological action from GLP-1 analogues, insulin, sulphonylureas or meglitinides, biguanides, peroxisome proliferator-activated receptor gamma (PPAR) agonists, alpha-glucosidase inhibitors, and amylin analogues. 
Sitagliptin se po kemijski strukturi in farmakološkem delovanju razlikuje od analogov GLP-1, insulina, sulfonilsečnin ali meglitinidov, bigvanidov, agonistov receptorjev gama, aktiviranih s peroksisomskim proliferatorjem (PPAR), zaviralcev alfa-glukozidaze in analogov amilina.
In a 52-week study, comparing the efficacy and safety of the addition of sitagliptin 100 mg once daily or glipizide (a sulphonylurea) in patients with inadequate glycaemic control on metformin monotherapy, sitagliptin was similar to glipizide in reducing HbA1c (-0.7 % mean change from baselines at week 52, with baseline HbA1c of approximately 7.5 % in both groups). 
V 52-tedenski študiji, v kateri so primerjali učinkovitost in varnost dodatnega zdravljenja s sitagliptinom v odmerku 100 mg enkrat na dan ali z glipizidom (sulfonilsečnina) pri bolnikih z neustrezno urejenostjo glikemije s samostojnim zdravljenjem z metforminom, je sitagliptin povzročil podobno zmanjšanje HbA1c kot glipizid (-0,7 % povprečna sprememba glede na začetno vrednost po 52 tednih, pri izhodiščni vrednosti HbA1c približno 7,5 % v obeh skupinah).
In monotherapy studies of sitagliptin 100 mg once daily alone compared to placebo, adverse reactions reported were headache, hypoglycaemia, constipation, and dizziness. 
V študijah samostojnega zdravljenja, v katerih so primerjali sitagliptin v odmerku 100 mg enkrat na dan in placebo, so poročali o naslednjih neželenih učinkih: glavobol, hipoglikemija, zaprtje in omotica.
The decrease in body weight with the combination of sitagliptin and metformin was similar to that observed with metformin alone or placebo; there was no change from baseline for patients on sitagliptin alone. 
Zmanjšanje telesne mase je bilo pri uporabi kombinacije sitagliptina in metformina podobno kot pri uporabi metformina samega ali placeba; telesna masa se pri bolnikih, ki so prejemali samo sitagliptin, v primerjavi z začetno vrednostjo ni spremenila.
When Ristfor is used in combination with insulin, a lower dose of insulin may be required to reduce the risk of hypoglycaemia (see section 4.4). 
Kadar se zdravilo Ristfor uporablja v kombinaciji z insulinom, bo morda potreben manjši odmerek insulina za zmanjšanje tveganja za hipoglikemijo (glejte poglavje 4.4).
Co-administration of multiple doses of sitagliptin (50 mg twice daily) and metformin (1,000 mg twice daily) did not meaningfully alter the pharmacokinetics of either sitagliptin or metformin in patients with type 2 diabetes. 
Pri sočasni uporabi večkratnih odmerkov sitagliptina (50 mg dvakrat na dan) in metformina (1.000 mg dvakrat na dan) se farmakokinetika sitagliptina ali metformina pri bolnikih s sladkorno boleznijo tipa 2 ni pomembno spremenila.
When Ristfor is used in combination with a sulphonylurea, a lower dose of the sulphonylurea may be required to reduce the risk of hypoglycaemia (see section 4.4). 
Kadar se zdravilo Ristfor uporablja v kombinaciji s sulfonilsečnino, bo morda potreben manjši odmerek sulfonilsečnine za zmanjšanje tveganja za hipoglikemijo (glejte poglavje 4.4).
Intravascular administration of iodinated contrast agents may lead to contrast-induced nephropathy, resulting in metformin accumulation and an increased risk of lactic acidosis. 
Intravaskularna aplikacija jodiranih kontrastnih sredstev lahko povzroči nefropatijo zaradi kontrastnega sredstva, ki povzroči kopičenje metformina in povečano tveganje laktacidoze.